CStone Pharmaceuticals ( (HK:2616) ) has provided an update.
CStone Pharmaceuticals has entered a strategic partnership with SteinCares to commercialize sugemalimab in 10 Latin American countries. This agreement marks CStone’s third major global commercialization deal for sugemalimab, which is already approved in the EU and UK for treating non-small cell lung cancer. The collaboration aims to leverage SteinCares’s extensive distribution network to enhance sugemalimab’s market penetration in Latin America, potentially benefiting a larger patient population and strengthening CStone’s position in the international market.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. The company has launched four innovative drugs and secured approvals for 16 new drug applications, addressing unmet medical needs in China and globally.
YTD Price Performance: 4.35%
Average Trading Volume: 2,449,954
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$3.03B
See more insights into 2616 stock on TipRanks’ Stock Analysis page.